Josep Llorens Sells 2,391 Shares of Haemonetics Co. (NYSE:HAE) Stock

Haemonetics Co. (NYSE:HAEGet Rating) EVP Josep Llorens sold 2,391 shares of the company’s stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $90.00, for a total value of $215,190.00. Following the sale, the executive vice president now owns 17,234 shares in the company, valued at approximately $1,551,060. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Haemonetics Stock Performance

NYSE:HAE traded down $0.11 during mid-day trading on Wednesday, reaching $90.49. 488,408 shares of the stock were exchanged, compared to its average volume of 501,157. The company has a 50 day simple moving average of $81.62 and a 200-day simple moving average of $77.20. The stock has a market capitalization of $4.58 billion, a P/E ratio of 54.58 and a beta of 0.39. The company has a quick ratio of 1.76, a current ratio of 2.73 and a debt-to-equity ratio of 1.04. Haemonetics Co. has a 1 year low of $43.50 and a 1 year high of $91.36.

Haemonetics (NYSE:HAEGet Rating) last released its quarterly earnings results on Monday, November 7th. The medical instruments supplier reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.70 by $0.13. The firm had revenue of $297.49 million for the quarter, compared to the consensus estimate of $273.92 million. Haemonetics had a return on equity of 20.05% and a net margin of 7.94%. Analysts anticipate that Haemonetics Co. will post 2.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the topic of a number of recent analyst reports. Citigroup increased their price objective on Haemonetics from $88.00 to $92.00 and gave the company a “neutral” rating in a report on Monday, December 12th. StockNews.com initiated coverage on Haemonetics in a report on Wednesday, October 12th. They issued a “buy” rating on the stock. Morgan Stanley dropped their price objective on Haemonetics from $90.00 to $84.00 and set an “equal weight” rating on the stock in a report on Friday, January 6th. Raymond James increased their price objective on Haemonetics from $88.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, November 8th. Finally, Barrington Research increased their price objective on Haemonetics from $88.00 to $94.00 and gave the company an “outperform” rating in a report on Tuesday, November 8th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $97.50.

Institutional Trading of Haemonetics

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in Haemonetics by 21.5% during the 1st quarter. Wellington Management Group LLP now owns 6,165,363 shares of the medical instruments supplier’s stock worth $389,776,000 after acquiring an additional 1,091,484 shares during the period. Capital Research Global Investors lifted its position in Haemonetics by 166.1% during the 1st quarter. Capital Research Global Investors now owns 5,452,006 shares of the medical instruments supplier’s stock worth $344,676,000 after acquiring an additional 3,402,873 shares during the period. Vanguard Group Inc. lifted its position in Haemonetics by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 5,195,195 shares of the medical instruments supplier’s stock worth $384,600,000 after acquiring an additional 173,113 shares during the period. Neuberger Berman Group LLC lifted its position in Haemonetics by 4.7% during the 3rd quarter. Neuberger Berman Group LLC now owns 3,893,389 shares of the medical instruments supplier’s stock worth $288,209,000 after acquiring an additional 174,545 shares during the period. Finally, Royce & Associates LP lifted its position in Haemonetics by 3.9% during the 3rd quarter. Royce & Associates LP now owns 874,808 shares of the medical instruments supplier’s stock worth $64,762,000 after acquiring an additional 33,223 shares during the period.

About Haemonetics

(Get Rating)

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.

Recommended Stories

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.